| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepacivirus | 8 | 2018 | 1509 | 1.67 | Why? |
| Nucleosides | 5 | 2021 | 221 | 1.28 | Why? |
| Hepatitis B virus | 6 | 2021 | 882 | 1.12 | Why? |
| Antiviral Agents | 23 | 2021 | 41703 | 1.06 | Why? |
| DNA-Directed RNA Polymerases | 2 | 2017 | 239 | 1.01 | Why? |
| Prodrugs | 4 | 2021 | 264 | 1.00 | Why? |
| Cytidine | 3 | 2021 | 219 | 0.97 | Why? |
| Norovirus | 3 | 2019 | 294 | 0.81 | Why? |
| Structure-Activity Relationship | 11 | 2021 | 2219 | 0.81 | Why? |
| Fluorine | 1 | 2017 | 7 | 0.74 | Why? |
| Hepatitis C, Chronic | 2 | 2018 | 973 | 0.70 | Why? |
| Lactones | 1 | 2017 | 62 | 0.68 | Why? |
| Molecular Structure | 8 | 2018 | 1539 | 0.66 | Why? |
| Ribonucleotides | 1 | 2017 | 96 | 0.65 | Why? |
| Peptidomimetics | 1 | 2018 | 202 | 0.63 | Why? |
| Peptide Hydrolases | 3 | 2019 | 1269 | 0.62 | Why? |
| Capsid | 1 | 2017 | 197 | 0.61 | Why? |
| DNA, Single-Stranded | 1 | 2016 | 95 | 0.59 | Why? |
| Behavior Therapy | 1 | 2018 | 235 | 0.57 | Why? |
| Benzamides | 1 | 2017 | 421 | 0.55 | Why? |
| Virus Assembly | 1 | 2017 | 438 | 0.54 | Why? |
| Capsid Proteins | 1 | 2017 | 365 | 0.52 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2019 | 433 | 0.52 | Why? |
| Imines | 1 | 2012 | 15 | 0.52 | Why? |
| Chikungunya virus | 1 | 2017 | 339 | 0.52 | Why? |
| HIV-1 | 8 | 2021 | 3365 | 0.52 | Why? |
| Enterocytes | 1 | 2016 | 245 | 0.52 | Why? |
| Hepatitis B, Chronic | 2 | 2017 | 616 | 0.50 | Why? |
| Parainfluenza Virus 3, Human | 1 | 2012 | 67 | 0.50 | Why? |
| Antitubercular Agents | 1 | 2019 | 775 | 0.48 | Why? |
| Amantadine | 1 | 2012 | 79 | 0.46 | Why? |
| DNA Fingerprinting | 1 | 2011 | 41 | 0.44 | Why? |
| SAM Domain and HD Domain-Containing Protein 1 | 3 | 2018 | 20 | 0.43 | Why? |
| Anti-HIV Agents | 3 | 2019 | 2209 | 0.43 | Why? |
| RNA | 3 | 2021 | 1278 | 0.41 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.41 | Why? |
| Purines | 4 | 2021 | 816 | 0.40 | Why? |
| Pyrimidines | 2 | 2017 | 1557 | 0.39 | Why? |
| Hepatitis B | 1 | 2018 | 888 | 0.39 | Why? |
| Cell Survival | 5 | 2018 | 1581 | 0.38 | Why? |
| Imidazoles | 1 | 2014 | 631 | 0.38 | Why? |
| HIV Infections | 6 | 2019 | 11620 | 0.38 | Why? |
| Virus Replication | 12 | 2021 | 14331 | 0.37 | Why? |
| Phosphoric Acids | 2 | 2017 | 9 | 0.36 | Why? |
| Georgia | 3 | 2020 | 955 | 0.35 | Why? |
| Lignans | 1 | 2007 | 41 | 0.34 | Why? |
| Dose-Response Relationship, Drug | 6 | 2021 | 3776 | 0.33 | Why? |
| Drug Discovery | 2 | 2020 | 3092 | 0.33 | Why? |
| Azetidines | 3 | 2021 | 722 | 0.32 | Why? |
| Influenza B virus | 1 | 2012 | 815 | 0.32 | Why? |
| Microbial Sensitivity Tests | 5 | 2018 | 2886 | 0.31 | Why? |
| Biphenyl Compounds | 1 | 2007 | 249 | 0.30 | Why? |
| Hep G2 Cells | 2 | 2017 | 391 | 0.30 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.30 | Why? |
| Sustained Virologic Response | 2 | 2018 | 378 | 0.29 | Why? |
| Cells, Cultured | 7 | 2021 | 5835 | 0.29 | Why? |
| Drug Repositioning | 2 | 2020 | 5683 | 0.29 | Why? |
| Mutagens | 2 | 2021 | 38 | 0.27 | Why? |
| Sofosbuvir | 2 | 2020 | 518 | 0.27 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.27 | Why? |
| Cell Line | 6 | 2020 | 12040 | 0.27 | Why? |
| Vero Cells | 7 | 2021 | 14117 | 0.26 | Why? |
| Viral Nonstructural Proteins | 3 | 2017 | 4810 | 0.26 | Why? |
| Gene Expression Regulation | 1 | 2016 | 4020 | 0.25 | Why? |
| Lymphocytes | 1 | 2016 | 3056 | 0.24 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.24 | Why? |
| Protease Inhibitors | 2 | 2019 | 3630 | 0.24 | Why? |
| Oxygen | 1 | 2016 | 3715 | 0.23 | Why? |
| Reverse Transcription | 3 | 2021 | 673 | 0.22 | Why? |
| Azo Compounds | 1 | 2021 | 39 | 0.22 | Why? |
| Propanolamines | 1 | 2020 | 47 | 0.22 | Why? |
| Substrate Specificity | 3 | 2017 | 639 | 0.22 | Why? |
| Organophosphonates | 1 | 2021 | 85 | 0.21 | Why? |
| Viral Proteins | 3 | 2019 | 7370 | 0.21 | Why? |
| Adenosine | 1 | 2005 | 509 | 0.21 | Why? |
| Influenza A virus | 1 | 2012 | 2234 | 0.21 | Why? |
| Neutrophil Infiltration | 1 | 2020 | 201 | 0.20 | Why? |
| Hydroxylamines | 1 | 2021 | 182 | 0.20 | Why? |
| Templates, Genetic | 1 | 2018 | 58 | 0.19 | Why? |
| Retroelements | 1 | 2018 | 27 | 0.19 | Why? |
| Simian Immunodeficiency Virus | 2 | 2018 | 251 | 0.19 | Why? |
| Transcription Activator-Like Effector Nucleases | 1 | 2018 | 4 | 0.19 | Why? |
| Acalculous Cholecystitis | 1 | 2018 | 7 | 0.19 | Why? |
| Viral Load | 3 | 2018 | 15850 | 0.18 | Why? |
| DNA, Circular | 1 | 2018 | 26 | 0.18 | Why? |
| Animals | 15 | 2021 | 78931 | 0.18 | Why? |
| DNA Polymerase beta | 1 | 2017 | 2 | 0.18 | Why? |
| RNA-Directed DNA Polymerase | 1 | 2018 | 170 | 0.18 | Why? |
| HIV-2 | 1 | 2018 | 92 | 0.18 | Why? |
| Stereoisomerism | 1 | 2017 | 121 | 0.18 | Why? |
| Pyrazoles | 4 | 2021 | 1791 | 0.17 | Why? |
| Sulfonamides | 3 | 2021 | 1294 | 0.17 | Why? |
| Monomeric GTP-Binding Proteins | 1 | 2017 | 12 | 0.17 | Why? |
| Macrophages | 3 | 2018 | 2784 | 0.17 | Why? |
| Simian Acquired Immunodeficiency Syndrome | 1 | 2018 | 154 | 0.16 | Why? |
| Lentivirus | 1 | 2018 | 310 | 0.16 | Why? |
| DNA, Complementary | 1 | 2018 | 568 | 0.16 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.16 | Why? |
| Models, Molecular | 5 | 2019 | 7616 | 0.15 | Why? |
| Amides | 2 | 2017 | 1864 | 0.15 | Why? |
| Encephalitis, Viral | 1 | 2020 | 355 | 0.15 | Why? |
| Virus Latency | 1 | 2017 | 251 | 0.15 | Why? |
| Adenine | 1 | 2018 | 463 | 0.15 | Why? |
| Bacteriophages | 1 | 2018 | 268 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| RNA, Viral | 6 | 2021 | 32276 | 0.14 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 275 | 0.14 | Why? |
| Humans | 39 | 2021 | 930598 | 0.13 | Why? |
| Catalytic Domain | 2 | 2019 | 1757 | 0.13 | Why? |
| Transgender Persons | 1 | 2018 | 322 | 0.13 | Why? |
| Zika Virus Infection | 2 | 2018 | 1920 | 0.13 | Why? |
| Macaca mulatta | 2 | 2020 | 3716 | 0.13 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.13 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.12 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 11367 | 0.12 | Why? |
| Sexual Partners | 1 | 2018 | 612 | 0.12 | Why? |
| Cell Proliferation | 2 | 2017 | 1973 | 0.12 | Why? |
| Valine | 1 | 2014 | 359 | 0.12 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.12 | Why? |
| Microsomes, Liver | 1 | 2012 | 96 | 0.12 | Why? |
| Sexual Health | 1 | 2018 | 419 | 0.12 | Why? |
| Coronavirus OC43, Human | 1 | 2020 | 1157 | 0.12 | Why? |
| Genotype | 2 | 2017 | 4697 | 0.12 | Why? |
| Respirovirus Infections | 1 | 2012 | 90 | 0.12 | Why? |
| Sequence Alignment | 2 | 2018 | 2109 | 0.12 | Why? |
| Janus Kinase Inhibitors | 1 | 2017 | 682 | 0.12 | Why? |
| CRISPR-Cas Systems | 2 | 2018 | 1397 | 0.11 | Why? |
| Drug Interactions | 1 | 2019 | 1653 | 0.11 | Why? |
| Cattle | 1 | 2016 | 1336 | 0.11 | Why? |
| Antineoplastic Agents | 1 | 2007 | 3550 | 0.11 | Why? |
| Carbamates | 1 | 2014 | 485 | 0.11 | Why? |
| HIV | 1 | 2018 | 1116 | 0.11 | Why? |
| Drug Design | 3 | 2019 | 2627 | 0.11 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.11 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.11 | Why? |
| Risk Reduction Behavior | 1 | 2018 | 946 | 0.11 | Why? |
| Pyrrolidines | 1 | 2014 | 558 | 0.10 | Why? |
| Cell Phone | 1 | 2018 | 750 | 0.10 | Why? |
| Sexually Transmitted Diseases | 1 | 2018 | 694 | 0.10 | Why? |
| Crystallography, X-Ray | 2 | 2019 | 2689 | 0.10 | Why? |
| Enzyme Inhibitors | 2 | 2018 | 1881 | 0.10 | Why? |
| Mutagenesis | 2 | 2021 | 394 | 0.09 | Why? |
| SARS Virus | 1 | 2012 | 13021 | 0.09 | Why? |
| Drug Evaluation, Preclinical | 1 | 2020 | 3347 | 0.09 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.09 | Why? |
| Cell Line, Tumor | 2 | 2021 | 3608 | 0.09 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.09 | Why? |
| DNA Mutational Analysis | 1 | 2011 | 581 | 0.09 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.09 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.09 | Why? |
| Escherichia coli | 2 | 2018 | 1547 | 0.09 | Why? |
| Point-of-Care Systems | 1 | 2021 | 2955 | 0.09 | Why? |
| Zika Virus | 2 | 2018 | 1924 | 0.08 | Why? |
| Cloning, Molecular | 1 | 2011 | 1036 | 0.08 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.08 | Why? |
| Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.08 | Why? |
| Telemedicine | 1 | 2018 | 25032 | 0.08 | Why? |
| Placenta | 1 | 2017 | 1531 | 0.08 | Why? |
| Boron Neutron Capture Therapy | 1 | 2005 | 1 | 0.08 | Why? |
| Thymidine | 1 | 2005 | 21 | 0.08 | Why? |
| DNA Primers | 1 | 2011 | 1170 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4545 | 0.08 | Why? |
| Boron Compounds | 1 | 2005 | 75 | 0.07 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Research | 1 | 2017 | 2115 | 0.07 | Why? |
| Drug Resistance, Viral | 1 | 2011 | 1083 | 0.07 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2018 | 5164 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Viral Regulatory and Accessory Proteins | 2 | 2018 | 482 | 0.06 | Why? |
| Molecular Docking Simulation | 2 | 2019 | 6902 | 0.06 | Why? |
| Amino Acid Sequence | 1 | 2014 | 6049 | 0.06 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.06 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.06 | Why? |
| Alkenes | 1 | 2021 | 41 | 0.06 | Why? |
| Genome, Viral | 2 | 2020 | 13157 | 0.05 | Why? |
| Cell Degranulation | 1 | 2020 | 130 | 0.05 | Why? |
| Methylation | 1 | 2021 | 332 | 0.05 | Why? |
| Mice | 2 | 2018 | 21357 | 0.05 | Why? |
| Viruses | 1 | 2013 | 2238 | 0.05 | Why? |
| Deoxyribonucleotides | 1 | 2018 | 3 | 0.05 | Why? |
| Bordetella | 1 | 2018 | 8 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.05 | Why? |
| Evaluation Studies as Topic | 1 | 2020 | 391 | 0.05 | Why? |
| Adult | 5 | 2020 | 244371 | 0.05 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.05 | Why? |
| CHO Cells | 1 | 2021 | 831 | 0.05 | Why? |
| Coinfection | 1 | 2019 | 6820 | 0.05 | Why? |
| Mutagenesis, Insertional | 1 | 2018 | 92 | 0.05 | Why? |
| Cricetulus | 1 | 2021 | 936 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Dideoxynucleotides | 1 | 2017 | 14 | 0.04 | Why? |
| Cell Death | 1 | 2020 | 536 | 0.04 | Why? |
| Point Mutation | 1 | 2021 | 481 | 0.04 | Why? |
| National Institutes of Health (U.S.) | 1 | 2020 | 443 | 0.04 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.04 | Why? |
| Arabinofuranosylcytosine Triphosphate | 1 | 2017 | 1 | 0.04 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Gallbladder | 1 | 2018 | 58 | 0.04 | Why? |
| Diagnostic Tests, Routine | 2 | 2021 | 2643 | 0.04 | Why? |
| Enzyme Stability | 1 | 2017 | 72 | 0.04 | Why? |
| Nervous System Malformations | 1 | 2017 | 43 | 0.04 | Why? |
| Public-Private Sector Partnerships | 1 | 2020 | 259 | 0.04 | Why? |
| Mutagenesis, Site-Directed | 1 | 2018 | 449 | 0.04 | Why? |
| Cytoplasm | 1 | 2018 | 304 | 0.04 | Why? |
| DNA Repair | 1 | 2017 | 114 | 0.04 | Why? |
| Virus Integration | 1 | 2017 | 96 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Fluorescence Resonance Energy Transfer | 1 | 2019 | 320 | 0.04 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2018 | 249 | 0.04 | Why? |
| Janus Kinases | 1 | 2020 | 414 | 0.04 | Why? |
| Sequence Analysis, Protein | 1 | 2018 | 309 | 0.04 | Why? |
| Hydrolysis | 1 | 2017 | 160 | 0.04 | Why? |
| Carbohydrates | 1 | 2017 | 51 | 0.04 | Why? |
| Inventions | 1 | 2020 | 372 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Cholecystectomy, Laparoscopic | 1 | 2018 | 120 | 0.04 | Why? |
| Triazoles | 1 | 2021 | 440 | 0.04 | Why? |
| Macrophages, Alveolar | 1 | 2020 | 668 | 0.04 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.04 | Why? |
| Green Fluorescent Proteins | 1 | 2017 | 450 | 0.04 | Why? |
| Americas | 1 | 2017 | 418 | 0.04 | Why? |
| Protein Stability | 1 | 2019 | 756 | 0.04 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.04 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.04 | Why? |
| Financing, Government | 1 | 2020 | 434 | 0.04 | Why? |
| Oxazines | 1 | 2017 | 279 | 0.04 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2021 | 881 | 0.04 | Why? |
| Primates | 1 | 2018 | 584 | 0.04 | Why? |
| Gene Deletion | 1 | 2017 | 430 | 0.04 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Benzimidazoles | 1 | 2018 | 275 | 0.04 | Why? |
| Pyrroles | 1 | 2017 | 292 | 0.04 | Why? |
| Polyproteins | 1 | 2018 | 814 | 0.04 | Why? |
| Nucleotides | 1 | 2017 | 212 | 0.03 | Why? |
| Proteolysis | 1 | 2018 | 751 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.03 | Why? |
| RNA Helicases | 1 | 2017 | 413 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2018 | 1517 | 0.03 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.03 | Why? |
| Nitriles | 1 | 2017 | 1053 | 0.03 | Why? |
| Cats | 1 | 2018 | 1890 | 0.03 | Why? |
| Male | 4 | 2020 | 367725 | 0.03 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.03 | Why? |
| Piperidines | 1 | 2017 | 795 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Female | 4 | 2020 | 380317 | 0.03 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.03 | Why? |
| Chickens | 1 | 2017 | 1010 | 0.03 | Why? |
| Cost-Benefit Analysis | 1 | 2020 | 2259 | 0.03 | Why? |
| Protein Multimerization | 1 | 2017 | 1336 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 13720 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.03 | Why? |
| Virion | 1 | 2018 | 1444 | 0.03 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.03 | Why? |
| Asia | 1 | 2017 | 2399 | 0.03 | Why? |
| Protein Interaction Domains and Motifs | 1 | 2017 | 2134 | 0.02 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2018 | 1672 | 0.02 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2012 | 12361 | 0.02 | Why? |
| Africa | 1 | 2017 | 2986 | 0.02 | Why? |
| Protein Conformation | 1 | 2019 | 4386 | 0.02 | Why? |
| Influenza, Human | 1 | 2012 | 10779 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| Middle Aged | 3 | 2020 | 270681 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.02 | Why? |
| Binding Sites | 1 | 2019 | 6201 | 0.02 | Why? |
| Tumor Cells, Cultured | 1 | 2005 | 254 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.02 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Aged | 1 | 2020 | 215776 | 0.02 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2020 | 10998 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.01 | Why? |
| Fibroblasts | 1 | 2005 | 839 | 0.01 | Why? |
| Serine Endopeptidases | 1 | 2017 | 4606 | 0.01 | Why? |
| Protein Binding | 1 | 2017 | 11430 | 0.01 | Why? |
| Cricetinae | 1 | 2005 | 3344 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Lung Neoplasms | 1 | 2005 | 3228 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.01 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.00 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |